Arcus Biosciences focus is another anti PD-1 therapy.
https://arcusbio.com/pipeline/chart/
Peak sales estimated at USD $3.3B + USD $1.5B = USD $4.8B (see below)
( this is speculatively about 5-10% of the revenue opportunity for Zantrene in Cancer )
Currently in Phase 2 & 3
Market cap USD $2.5B
https://www.bloombergquint.com/busi...reet-touts-10-billion-opportunity-with-gilead
RACE will have 5 x Phase 2 trials underway by the end of 2022, not forgetting the track-record of historic approval for AML (Phase 3 / 4 history).
Industry news, page-160
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.000(0.00%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.66 | $1.61 | $117.0K | 71.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12252 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 900 | 1 |
View Market Depth
| Last trade - 16.10pm 29/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |